Skip to main content
Chiome Bioscience Inc. logo

Chiome Bioscience Inc. — Investor Relations & Filings

Ticker · 4583 ISIN · JP3205350006 T Professional, scientific and technical activities
Open in API
Filings indexed 70 across all filing types
Latest filing 2026-03-27 Regulatory Filings
Country JP Japan
Listing T 4583

About Chiome Bioscience Inc.

https://www.chiome.co.jp/

Chiome Bioscience Inc. is a clinical-stage biotechnology company specializing in the research and development of antibody-based therapeutics. The company leverages its proprietary ADLib® system, an innovative antibody generation technology, to discover and develop fully human monoclonal antibodies. Its primary mission is to address unmet medical needs by creating novel antibody drugs. The company's operations focus on the early stages of the drug discovery and development process, including initial research and early-phase clinical trials.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is titled '確認書' (Confirmation Letter) and explicitly states it is filed under the Financial Instruments and Exchange Act Article 24-4-2. It serves as an officer certification confirming the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a report, should be classified as Regulatory Filings (RNS) rather than the report itself. FY 2025
2026-03-27 Japanese
有価証券報告書－第22期(2025/01/01－2025/12/31)
Annual Report Classification · 1% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains comprehensive financial statements, business descriptions, and management analysis for the fiscal year ending December 31, 2025. It is a formal regulatory filing submitted to the Kanto Local Finance Bureau. FY 2025
2026-03-27 Japanese
有価証券届出書（組込方式）
Capital/Financing Update Classification · 1% confidence The document is a 'Securities Registration Statement' (有価証券届出書) filed with the Kanto Local Finance Bureau by Chiome Bioscience Inc. It details the issuance of new share acquisition rights (stock options/warrants) and convertible bonds. This type of regulatory filing, which outlines the terms of a capital raise, falls under the 'Capital/Financing Update' category as it describes specific fundraising activities and capital structure changes.
2025-11-28 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically related to the accuracy of the semi-annual report (第２四半期報告書). While it references the semi-annual report, the document itself is a regulatory filing confirming the validity of the financial statements for the period ending June 30, 2025. Since it is a specific regulatory requirement for filing financial reports in Japan and does not fit into the other categories like 'IR' (which would be the report itself) or 'RPA' (which is an announcement of a report), it is best classified as a Regulatory Filing.
2025-08-12 Japanese
半期報告書－第22期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 1% confidence The document is a '半期報告書' (Semi-Annual Report) for Chiome Bioscience Inc., covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial statements, management analysis of financial conditions, and operational results, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-12 Japanese
内部統制報告書－第21期(2024/01/01－2024/12/31)
Governance Information Classification · 1% confidence The document explicitly states its title and basis in the header table: "【提出書類】 内部統制報告書" (Document Submitted: Internal Control Report) and cites the legal basis as "金融商品取引法第24条の４の４第１項" (Financial Instruments and Exchange Act Article 24-4-4, Paragraph 1). The content discusses the framework, scope, and results of evaluating internal controls over financial reporting ("財務報告に係る内部統制"). This directly corresponds to the definition of an Audit Report / Information (AR), which covers internal or regulatory stress tests and applied accounting principles, although this specific document is a Japanese statutory Internal Control Report (which is closely related to the audit/control assurance function). However, looking closely at the provided definitions, 'AR' is defined as 'Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests (excluding full Annual Reports)'. While an Internal Control Report is a specific Japanese filing, it serves the function of reporting on internal controls, which aligns best with the scope covered by 'AR' compared to other options like 10-K (full annual report) or ER (earnings release). Given the focus on internal control assessment, AR is the most appropriate fit among the choices, as it deals with assurance/control reporting outside of the main 10-K. Since the document is the report itself and not an announcement of a report, RPA/RNS is ruled out. The length (1807 chars) suggests it is a substantive filing, not just a brief announcement.
2025-03-28 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.